Thank you for scheduling time with Durbin. We are excited to discuss with you how EAPs can help you achieve success for your orphan drug. A member of our team will reach out to you shortly with confirmation.
In the meantime, access first-rate resources below that can start answering your most pressing questions right now!
CASE STUDY
A Truly Global Expanded Access Program: Navigating Diverse Regulatory Requirements to Deliver a Gene Therapy
Read More
WHITE PAPER
When Clinical Trials Are Not Enough: How Expanded Access Programs Benefit Clinical to Commercial Transitions
Read in our white paper how forward-thinking biotechs are realizing the benefits of including EAPs in their clinical to commercial strategy.
CASE STUDY
BEYOND THE PANDEMIC: Solving Surprising Expanded Access Program Supply Chain Challenges
The pharmaceutical had a controlled drug status which was the first of its kind to be included in an EAP.
INSIGHTS
Evaluating the Cost Impact of an Expanded Access Program
The ultimate goal of an EAP is to provide much-needed treatment to patients who have an urgent need, but companies must find balance in managing program costs.